ClinicalTrials.gg
RecruitingNCT05025605Updated Aug 11, 2026

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

A Phase 1 interventional study of BXCL501 80 Micrograms and Placebo Film in Schizophrenia, Schizo-Affective Disorder and Schizophreniform; Schizophrenic, sponsored by BioXcel Therapeutics Inc. Recruiting at 5 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by BioXcel Therapeutics Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,466 studies in Schizophrenia with a site in United States — 149 open to participants now, 167 under way, 22 of them phase 3. Schizophrenia · United States.

Planned enrollment
390th of 1,320
140 · median 66
Started
2021
with 52 others
Phase 1
196 of 1,466
10 open now
Primary completion
2027-07
later than 69 of 166 live
Registered
1,228th of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 390th largest by planned enrollment of the 1,320 interventional ones that give a count, is one of 53 that started in 2021, is one of 196 in phase 1, reaches primary completion later than 69 of the 166 other live ones, and was the 1,228th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

149 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

Read the detailed description

The study will enroll approximately 140 subjects randomized to dose regimens of 80 µg or 120 µg BCXL501 or placebo (Group one), or 60 µg BCXL501 or placebo (Group two; Europe only). Subjects with acute agitation will include male and female children and adolescents who are either newly admitted to a hospital setting or already admitted and experiencing acute agitation. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing.

03

Conditions studied

  • Schizophrenia
  • Schizo-Affective Disorder
  • Schizophreniform; Schizophrenic
  • Bipolar Disorder I
  • Bipolar Disorder II
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects between the ages of 10-17 years, inclusive, with bipolar disorder ( criteria) and 13-17 years, inclusive, in subjects with schizophrenia (DSM-5 criteria).
  2. Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥14 on the 5 items comprising the PANSS Excited Component (PEC).
  3. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.
  4. Participants who agree to use a medically acceptable and effective method

Exclusion criteria

Exclusion Criteria:

  1. Patients with agitation caused by acute intoxication, including alcohol or drugs of abuse (with the exception of THC) during urine screening.
  2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular antipsychotic drugs in the 4 hours before study treatment.
  3. Patients who are judged to be at significant risk of suicide.
  4. Patients with serious or unstable medical illnesses.
  5. Patients who have received an drug within 30 days prior to the current agitation episode.
  6. Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving the study drug.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    80 Micrograms

    Sublingual film containing 80 micrograms Dexmedetomidine

    Drug: BXCL501 80 Micrograms

  • Experimental
    120 Micrograms

    Sublingual film containing 120 micrograms Dexmedetomidine

    Drug: BXCL501 120 Micrograms

  • Placebo comparator
    Placebo

    Sublingual Placebo film

    Drug: Placebo Film

  • Experimental
    60 Micrograms

    Sublingual film containing 60 micrograms Dexmedetomidine Europe Only

    Drug: BXCL501 60 Micrograms

Interventions

  • Sublingual film containing 80 Micrograms BXCL501

    Also known as: Dexmedetomidine

  • DrugPlacebo Film

    Matching Sublingual Placebo film

    Also known as: Placebo

  • Sublingual film containing 120 Micrograms BXCL501

    Also known as: Dexmedetomidine

  • Sublingual film containing 60 Micrograms BXCL501 Europe Only

    Also known as: Dexmedetomidine

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score

    The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)

    Time frame: 120 minutes - Group one only

Secondary outcomes

  1. Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score

    The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)

    Time frame: 90, 60, 45, 30, 20,10 minutes - Group one only

07

Study locations

4 of 5 sites recruiting
  • BioXcel Clinical Research Site
    Anaheim, California 92805, United States
    Recruiting
  • Bioxcel Clinical Research Site
    Hialeah, Florida 33016, United States
    Recruiting
  • BioXcel Clinical Research Site
    Atlanta, Georgia 30331, United States
    Completed

    Not enrolling at this site.

  • Bioxcel Clinical Research Site
    Decatur, Georgia 30030, United States
    Recruiting
  • BioXcel Clinical Research Site
    DeSoto, Texas 75115, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Jul 2027, 71 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 71 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 27, 2021
StartActual
Aug 27, 2021
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05025605
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
ProPharma Group
Responsible party
Sponsor
First posted
Aug 27, 2021
Start date
Aug 27, 2021
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

BioXcel CTM
Contact
info@bioxceltherapeutics.com
475-238-6837
BioXcel MM, MD
study chair · BioXcel Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion